Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the methicillin-resistant Staphylococcus aureus (MRSA) drug market to increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Methicillin-Resistant Staphylococcus Aureus find that Forest/AstraZeneca/Takeda's ceftaroline and Trius's torezolid will capture more than one-third of the MRSA drug market in 2019. A new drug application for ceftaroline for complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia was filed in the fourth quarter of 2009, and torezolid -- a second generation oxazolidinone -- is expected to begin Phase III clinical trials for cSSSI by end of 2010.

"In light of Pfizer's blockbuster success with Zyvox, which is the only MRSA therapy with interchangeable IV/oral formulations, several other companies are now developing drugs with interchangeable IV/oral formulations," said Decision Resources Analyst Charu Vepari, Ph.D. "Torezolid, if approved, would join Zyvox as the second oxazolidinone with IV/oral formulations available in the MRSA drug market."

The Pharmacor 2010 findings also reveal that leading infectious disease experts in the U.S. and Europe consider the increased availability of oral formulations to be a key unmet need for MRSA treatment. Interviewed key opinion leaders indicate that the availability of additional oral MRSA therapies would offer a significant advantage over intravenous therapies, particularly in outpatient settings, community-acquired MRSA infections and infections such as osteomyelitis which require long-term treatment.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, Inc.,

Satisfied With Stelara's Efficacy and Dosing, Nearly Three-Quarters of Surveyed Dermatologists Will Increase Its Use for the Treatment of Psoriasis Over the Next Year

View Now